危急病患者中XII因子缺乏的发生率,长期活化部分血栓形成时间:前性观察性研究
Lipi Mishra1, David Lee, Kwok M Ho
1Medical School, University of Western Australia, and School of Veterinary & Life Sciences, Murdoch University, Intensive Care Unit, Royal Perth Hospital, Western Australia, Australia.
概括
在患有长期活化部分血栓形成时间 (aPTT) 的重症患者中,XII因子缺乏症很常见. 这项研究没有发现这些患者与XII因子缺乏相关的血栓栓塞的风险增加.
科学领域:
- 血液学 血液学 血液学
- 关键护理医学 关键护理医学
- 血栓形成研究研究
背景情况:
- 有限的数据存在于危急病患者的XII因子缺乏症呈现长期活化部分血栓形成时间 (aPTT).
- 在这个人群中,XII因子缺乏和血栓塞栓事件的风险之间的关系尚不清楚.
研究的目的:
- 确定因子XII缺乏症在患有长期aPTT的重症患者中的发生率.
- 调查XII因子缺乏是否与血栓栓塞的风险增加有关.
- 评估旋转性血栓形成显微镜 (ROTEM) 凝血时间在预测XII因子缺乏症方面的实用性.
主要方法:
- 一项前性观察性研究,涉及重症患者,aPTT>40秒.
- 评估XII因子水平,血栓塞栓事件,输血和死亡率.
- 分析ROTEM凝血时间,以预测XII因子缺乏.
主要成果:
- 在48%的患者中观察到XII因子缺乏;水平与aPTT无关.
- 缺乏XII因子在不那么严重的患者中更常见,并且与DIC得分无关.
- 在XII因子缺乏和缺乏XII因子缺乏的患者之间,在症状性静脉血栓栓塞,输血或死亡率方面没有发现显著差异.
- ROTEM凝血时间不是XII因子缺乏的可靠预测指标.
结论:
- 在患有长期aPTT的重症患者中,XII因子缺乏症很普遍.
- 在这种情况下,XII因子缺乏与血栓栓塞的风险增加无关.
- 对于预测这个患者群体的XII因子缺乏症,ROTEM并不有用.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
13
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
13
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.4K
01:24Disorders of Hemostasis
1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K